279
Views
7
CrossRef citations to date
0
Altmetric
Atopic dermatitis and other inflammatory skin diseases

Factors determining the effectiveness of oral ciclosporin in the treatment of severe childhood atopic dermatitis

&
Pages 318-322 | Received 10 Jan 2012, Accepted 05 Feb 2012, Published online: 12 Apr 2012
 

Abstract

Ciclosporin is used to treat severe atopic dermatitis (AD) where conventional therapy is either ineffective or inappropriate. Response to treatment is variable and the factors determining responsiveness are currently unclear. The aim of this study was to determine which children with severe AD are most responsive. A cohort of 35 children with severe AD who were given oral ciclosporin was retrospectively surveyed. SCORAD index was used to assess severity prior to and after treatment. Demographic and clinical data were correlated with clinical response. Ciclosporin resulted in a sustained reduction in SCORAD index of 91 (67–100)% in children where clinical skin infection was the main trigger and in whom the infection was effectively eradicated with antibiotics. If infection persisted or recurred the reduction in SCORAD index was only 44 (41–83)%. Children in whom their AD was triggered by other factors had a poor response to ciclosporin with reduction in SCORAD index of 8 (1–39)%. Oral ciclosporin is most effective in children with infection-driven AD in whom the infection is brought under control. In cases where the infection recurs or where the main triggers are non-infectious, response to ciclosporin is poorer.

Declaration of interest: The authors report no conflict of interests. The authors alone are responsible for the content and writing of the paper.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.